Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/20—Oxygen atoms
  • C07D215/22—Oxygen atoms attached in position 2 or 4
  • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/235—Saturated compounds containing more than one carboxyl group
  • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
  • C07C59/265—Citric acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the invention relates to a novel solid form of (li?,2S)-l-(6-bromo-2-methoxy-3-quinolyl)-4- dimethylamino-2-(l-naphthyl)-l- henyl-butan-2-ol of formula (I),
• bedaquiline ( 1 R,2S)- 1 -(6-Bromo-2-methoxy-3 -quinolyl)-4-dimethylamino-2-( 1 -naphthyl)- 1 -phenyl- butan-2-ol
• bedaquiline (CAS no. 843663-66-1) and belongs to the group of quinoline derivatives that can be used as microbial inhibitors.
• the salt bedaquiline fumarate (1:1) is suitable for treatment or prevention of resistant microbial infections, especially microbial tuberculosis infections.
• Bedaquiline fumarate exists in one non-solvated crystalline form (Form A) and two pseudo- polymorphic forms B and C.
• the invention provides a solid form of bedaquiline with citric acid and methods of its preparation.
• the crystalline salt is prepared by a reaction of bedaquiline in the free base form with citric acid in a suitable solvent or mixtures of solvents.
• the prepared salt has advantageous physical-chemical characteristics for use in the pharmaceutical industry and in formulation of new dosage forms.
• FIG. 1 X-ray powder pattern of bedaquiline citrate (prepared in accordance with Process 2).
• Figure 2. IR spectrum of bedaquiline citrate (prepared in accordance with Process 2).
• a crystalline product is often stable, its required purity is easier to achieve and it dissolves more slowly.
• This invention provides a crystalline salt of bedaquiline in the solid phase.
• the invention provides a novel solid form of bedaquiline with citric acid that can be prepared and isolated in a crystalline form in adequate yields with high chemical purity.
• This solid form can be both anhydrous or non-solvated and in the form of hydrates/solvates of the respective solvents.
• the prepared novel solid form of bedaquiline may have various internal arrangements (polymorphism) with different physical-chemical properties depending on the conditions of its preparation. For this reason, the invention relates to the crystalline form of bedaquiline with citric acid or its mixtures in any ratio.
• This solid form is suitable for preparation and isolation of bedaquiline with high chemical and optical purity.
• the preparation of the solid form of bedaquiline of formula I is carried out by reaction of the free base of bedaquiline with citric acid.
• the reaction is conducted in a suitable solvent, which can be ketones, esters, ethers, amides, nitriles or organic acids, alcohols, aliphatic and aromatic hydrocarbons, chlorinated hydrocarbons, water or their mixtures.
• Aliphatic Q-C4 alcohols, esters or their mixtures are preferred.
• the most commonly used solvents are isopropanol, acetonitrile, tetrahydrofuran or their mixtures.
• the final product is typically precipitated or crystallized at temperatures in the range of -30°C to the boiling point of the solvent.
• the crystalline form of bedaquiline citrate (according to Example 2) is characterized by the reflections presented in Table 1.
• Table 1 includes reflections whose relative intensity value is higher than 1 percent.
• the characteristic diffraction peaks of bedaquiline citrate in accordance with this invention are as follows: 10.3; 12.0; 13.1; 18.3; 19.7 and 22,0 ⁇ 0.2° 2-theta.
• An example of the X-ray powder pattern is shown in Figure 1.
• the melting point of bedaquiline citrate is 174°C (DSC).
• a 10mm mask and a 1/4° fixed anti-dispersion slit were used.
• the irradiated area of the sample is 10 mm, programmable divergence slits were used.
• For the correction of the secondary array 0.02 rad Soller slits and a 5.0 anti-dispersion slit were used.
• ATR (ZnSe - single reflection) infrared spectra of the powder samples were measured with an infrared spectrometer (Nicolet Nexus, Thermo, USA) equipped with a DTGS KBr detector, in the measurement range of 600-4000 cm '1 and the spectral resolution of 4.0 cm "1 .
• the data were obtained at 64 spectrum accumulations.
• the OMNIC 6.2 software was used to process the spectra.
• the record of bedaquiline citrate was measured using a Discovery DSC device made by TA Instruments.
• the sample charge in a standard Al pot (40 yiL) was 4-5 mg and the heating rate was 5°C/min.
• As the carrier gas 5.0 N 2 was used at the flow rate of 50 ml/min.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pulmonology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=56463987

Family Applications (1)

Country Status (2)

Citations (4)

• 2015
  • 2015-06-09 CZ CZ2015-391A patent/CZ2015391A3/cs unknown
• 2016
  • 2016-06-03 WO PCT/CZ2016/000063 patent/WO2016198031A1/en not_active Ceased

Patent Citations (5)

Also Published As

Similar Documents

Legal Events